| scholarly article | Q13442814 |
| P50 | author | Hirofumi Mukai | Q90836125 |
| Satoshi Fujii | Q114834103 | ||
| P2093 | author name string | Youngjin Park | |
| Satoshi Yamashita | |||
| Takeshi Yamaguchi | |||
| Reiki Nishimura | |||
| Yasuaki Sagara | |||
| Shigeru Imoto | |||
| Hiromitsu Akabane | |||
| Masato Takahashi | |||
| Tomomi Fujisawa | |||
| Tsutomu Takashima | |||
| Shozo Ohsumi | |||
| Tatsuya Toyama | |||
| Yasuo Hozumi | |||
| Yukari Uemura | |||
| Toshiro Mizuno | |||
| P2860 | cites work | Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 | Q28085062 |
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized | Q31089499 | ||
| Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group | Q35552069 | ||
| Proliferation marker Ki-67 in early breast cancer | Q36271525 | ||
| Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry | Q36892788 | ||
| Ki67 in breast cancer: prognostic and predictive potential | Q37691691 | ||
| Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer | Q37766549 | ||
| Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. | Q40835681 | ||
| Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study | Q42941886 | ||
| A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients | Q43060768 | ||
| Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall | Q43180234 | ||
| Prognostic significance of tumor cell proliferation analyzed in fine needle aspirates from primary breast cancer | Q43907667 | ||
| Response-guided neoadjuvant chemotherapy for breast cancer. | Q52882601 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. | Q53394493 | ||
| Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). | Q53396920 | ||
| Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over | Q73445633 | ||
| Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer | Q80348116 | ||
| The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer | Q81557497 | ||
| Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression | Q87873388 | ||
| P921 | main subject | preoperative chemotherapy | Q108532530 |
| P577 | publication date | 2020-04-02 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study |
Search more.